With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
MarketBeat on MSN2d
What Does the Future Hold for Eli Lilly?GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Black History Month is starts this weekend, and as an avid reader, I'm thinking about books by Black authors that I'd love to ...
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
Just before Christmas, I was asked to interview singer and actress Lily Allen on stage at an event to mark Addiction Awareness Week. I've interviewed a lot of high profile people in my career ...
Authoritative and well-researched, Chemically Imbalanced documents the overinflation of antidepressant efficacy, where the ...
On that note, time to hustle. Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
Shares of Eli Lilly and Co. fell more than 7% in midday trading Tuesday after the Indianapolis company announced its fourth quarter revenue would fall short of expectations. Lilly said its U.S ...
Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small molecule precision oncology therapies, have announced a definitive agreement for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback